Abstract
Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab (IVB) on DR including DME and PDR at 24 months of follow up. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse diabetic macular edema. Therefore, in the future this new therapy could replace or complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to pan-retina photocoagulation so that more selective therapy may be applied. In addition, we report a series of patients in which tractional retinal detachment developed or progressed after adjuvant preoperative IVB in severe PDR.
Keywords: Diffuse diabetic macular edema, Proliferative diabetic retinopathy, Panretinal photocoagulation, Tractional retinal detachment, Vascular endothelial growth factor, Intravitreal bevacizumab, Diabetic retinopathy (DR), Diabetic macular edema (DME), ischemia, focal/grid laser photocoagulation, pan-retina photocoagulation, anti-VEGF, ETDRS, Diabetes Control and Complications Trial (DCCT), Retinal neovascularization, Fluorescein angiography, Neovascularization, Diabetic Retinopathy Study (DRS), Bevacizumab, related-macular degeneration (AMD), Optical coherence tomography
Current Diabetes Reviews
Title: Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Volume: 6 Issue: 5
Author(s): J. Fernando Arevalo, Juan G. Sanchez, Andres F. Lasave, Lihteh Wu, Mauricio Maia, Sergio Bonafonte, Miguel Brito, Arturo A. Alezzandrini, Natalia Restrepo, Maria H. Berrocal, Mario Saravia, Michel E. Farah, Jans Fromow-Guerra and Virgilio Morales-Canton
Affiliation:
Keywords: Diffuse diabetic macular edema, Proliferative diabetic retinopathy, Panretinal photocoagulation, Tractional retinal detachment, Vascular endothelial growth factor, Intravitreal bevacizumab, Diabetic retinopathy (DR), Diabetic macular edema (DME), ischemia, focal/grid laser photocoagulation, pan-retina photocoagulation, anti-VEGF, ETDRS, Diabetes Control and Complications Trial (DCCT), Retinal neovascularization, Fluorescein angiography, Neovascularization, Diabetic Retinopathy Study (DRS), Bevacizumab, related-macular degeneration (AMD), Optical coherence tomography
Abstract: Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab (IVB) on DR including DME and PDR at 24 months of follow up. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse diabetic macular edema. Therefore, in the future this new therapy could replace or complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to pan-retina photocoagulation so that more selective therapy may be applied. In addition, we report a series of patients in which tractional retinal detachment developed or progressed after adjuvant preoperative IVB in severe PDR.
Export Options
About this article
Cite this article as:
Fernando Arevalo J., G. Sanchez Juan, F. Lasave Andres, Wu Lihteh, Maia Mauricio, Bonafonte Sergio, Brito Miguel, A. Alezzandrini Arturo, Restrepo Natalia, H. Berrocal Maria, Saravia Mario, E. Farah Michel, Fromow-Guerra Jans and Morales-Canton Virgilio, Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture, Current Diabetes Reviews 2010; 6 (5) . https://dx.doi.org/10.2174/157339910793360842
DOI https://dx.doi.org/10.2174/157339910793360842 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Effects of Insulin on the Vasculature
Current Vascular Pharmacology The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design Creation of Retinal Vein Occlusion Model in Cynomolgus Monkeys and Determination of its Pathological Features
Current Neurovascular Research Anti-angiogenic Drugs as an Adjunctive Therapy in the Surgical Treatment of Diabetic Retinopathy
Current Diabetes Reviews Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Thrombosis in Paroxysmal Nocturnal Hemoglobinuria at a Glance: A Clinical Review
Current Vascular Pharmacology Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design